Reply to Ki67 in breast cancer: A useful prognostic marker!

Annals of Oncology

Volumn 25, Issue 2, 2014, Pages 542-

  Denkert, C ^a   von Minckwitz, G ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b German Breast Group   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TUMOR MARKER;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER REGISTRY; CANCER RISK; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; HUMAN; LETTER; PATIENT SELECTION; PRIORITY JOURNAL; REFERENCE VALUE; RISK ASSESSMENT; STANDARDIZATION; TREATMENT RESPONSE; TUMOR BIOPSY; BREAST TUMOR; FEMALE; GENETICS;

BREAST NEOPLASMS; FEMALE; HUMANS; KI-67 ANTIGEN; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 84893344417     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt564     Document Type: Letter

References (3)

1. Caldarella A, Crocetti E, Paci E. Ki67 in breast cancer: a useful prognostic marker?. Ann Oncol 2014; 25: 542.
2. Denkert C, Loibl S, Müller BM et al. Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. Ann Oncol 2013; 24(11): 2786-2793.
3. Budczies J, Klauschen F, Sinn BV et al. Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS One 2012; 7(12): e51862.